167 related articles for article (PubMed ID: 38570073)
1. Drug product Formulation and Fill/Finish Manufacturing Process Considerations for AAV-Based Genomic Medicines.
Som M; Gikanga B; Kanapuram V; Yadav S
J Pharm Sci; 2024 Jul; 113(7):1711-1725. PubMed ID: 38570073
[TBL] [Abstract][Full Text] [Related]
2. Manufacturing Challenges and Rational Formulation Development for AAV Viral Vectors.
Srivastava A; Mallela KMG; Deorkar N; Brophy G
J Pharm Sci; 2021 Jul; 110(7):2609-2624. PubMed ID: 33812887
[TBL] [Abstract][Full Text] [Related]
3. Improved Genome Packaging Efficiency of Adeno-associated Virus Vectors Using Rep Hybrids.
Mietzsch M; Eddington C; Jose A; Hsi J; Chipman P; Henley T; Choudhry M; McKenna R; Agbandje-McKenna M
J Virol; 2021 Sep; 95(19):e0077321. PubMed ID: 34287038
[TBL] [Abstract][Full Text] [Related]
4. Quality Control Testing, Characterization and Critical Quality Attributes of Adeno-Associated Virus Vectors Used for Human Gene Therapy.
Wright JF
Biotechnol J; 2021 Jan; 16(1):e2000022. PubMed ID: 33146911
[TBL] [Abstract][Full Text] [Related]
5. Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling.
Kienle E; Senís E; Börner K; Niopek D; Wiedtke E; Grosse S; Grimm D
J Vis Exp; 2012 Apr; (62):. PubMed ID: 22491297
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.
Arjomandnejad M; Dasgupta I; Flotte TR; Keeler AM
BioDrugs; 2023 May; 37(3):311-329. PubMed ID: 36862289
[TBL] [Abstract][Full Text] [Related]
7. Evolving AAV-delivered therapeutics towards ultimate cures.
He X; Urip BA; Zhang Z; Ngan CC; Feng B
J Mol Med (Berl); 2021 May; 99(5):593-617. PubMed ID: 33594520
[TBL] [Abstract][Full Text] [Related]
8. Challenges in scaling up AAV-based gene therapy manufacturing.
Jiang Z; Dalby PA
Trends Biotechnol; 2023 Oct; 41(10):1268-1281. PubMed ID: 37127491
[TBL] [Abstract][Full Text] [Related]
9. Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications.
Schön C; Biel M; Michalakis S
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):343-52. PubMed ID: 25615882
[TBL] [Abstract][Full Text] [Related]
10. scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution.
Öztürk BE; Johnson ME; Kleyman M; Turunç S; He J; Jabalameli S; Xi Z; Visel M; Dufour VL; Iwabe S; Pompeo Marinho LFL; Aguirre GD; Sahel JA; Schaffer DV; Pfenning AR; Flannery JG; Beltran WA; Stauffer WR; Byrne LC
Elife; 2021 Oct; 10():. PubMed ID: 34664552
[TBL] [Abstract][Full Text] [Related]
11. The ice age - A review on formulation of Adeno-associated virus therapeutics.
Grossen P; Skaripa Koukelli I; van Haasteren J; H E Machado A; Dürr C
Eur J Pharm Biopharm; 2023 Sep; 190():1-23. PubMed ID: 37423416
[TBL] [Abstract][Full Text] [Related]
12. Development of Gene Therapy Vectors: Remaining Challenges.
Gupta V; Lourenço SP; Hidalgo IJ
J Pharm Sci; 2021 May; 110(5):1915-1920. PubMed ID: 33279518
[TBL] [Abstract][Full Text] [Related]
13. New recombinant serotypes of AAV vectors.
Gao G; Vandenberghe LH; Wilson JM
Curr Gene Ther; 2005 Jun; 5(3):285-97. PubMed ID: 15975006
[TBL] [Abstract][Full Text] [Related]
14. Vectrology of adeno-associated viruses (AAV).
Skubis-Zegadło J; Stachurska A; Małecki M
Med Wieku Rozwoj; 2013; 17(3):202-6. PubMed ID: 24296444
[TBL] [Abstract][Full Text] [Related]
15. Development of a stable lyophilized adeno-associated virus gene therapy formulation.
Zhang YZ; DePaz RA; Bee JS; Marshall T
Int J Pharm; 2021 Sep; 606():120912. PubMed ID: 34298099
[TBL] [Abstract][Full Text] [Related]
16. Various AAV Serotypes and Their Applications in Gene Therapy: An Overview.
Issa SS; Shaimardanova AA; Solovyeva VV; Rizvanov AA
Cells; 2023 Mar; 12(5):. PubMed ID: 36899921
[TBL] [Abstract][Full Text] [Related]
17. Analytical characterization of full, intermediate, and empty AAV capsids.
McColl-Carboni A; Dollive S; Laughlin S; Lushi R; MacArthur M; Zhou S; Gagnon J; Smith CA; Burnham B; Horton R; Lata D; Uga B; Natu K; Michel E; Slater C; DaSilva E; Bruccoleri R; Kelly T; McGivney JB
Gene Ther; 2024 May; 31(5-6):285-294. PubMed ID: 38374348
[TBL] [Abstract][Full Text] [Related]
18. Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.
Chamberlain K; Riyad JM; Weber T
Hum Gene Ther Methods; 2016 Feb; 27(1):1-12. PubMed ID: 26757051
[TBL] [Abstract][Full Text] [Related]
19. The state of the art of adeno-associated virus-based vectors in gene therapy.
Coura Rdos S; Nardi NB
Virol J; 2007 Oct; 4():99. PubMed ID: 17939872
[TBL] [Abstract][Full Text] [Related]
20. High-Throughput
Westhaus A; Cabanes-Creus M; Rybicki A; Baltazar G; Navarro RG; Zhu E; Drouyer M; Knight M; Albu RF; Ng BH; Kalajdzic P; Kwiatek M; Hsu K; Santilli G; Gold W; Kramer B; Gonzalez-Cordero A; Thrasher AJ; Alexander IE; Lisowski L
Hum Gene Ther; 2020 May; 31(9-10):575-589. PubMed ID: 32000541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
